Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group

Gynecologic Oncology

Volumn 96, Issue 1, 2005, Pages 103-107

  Schilder, Russell J ^a   Blessing, John ^b   Cohn, David E ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Gemcitabine; Non squamous cell cervical cancer

Indexed keywords

ANTIBIOTIC AGENT; GEMCITABINE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG FATALITY; DRUG FEVER; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HYPOKALEMIA; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LUNG TOXICITY; METABOLIC DISORDER; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECTOVAGINAL FISTULA; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; CARCINOMA, ADENOSQUAMOUS; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; UTERINE CERVICAL NEOPLASMS;

EID: 10044252050     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.09.027     Document Type: Article

References (29)

1. A. Jemal, T. Murray, A. Samuels, A. Ghafoor, E. Ward, and M.J. Thun Cancer statistics, 2003 CA Cancer. J. Clin. 53 2003 5 26
2. SEER Cancer Statistics Review, 1973-1996 (NCI 1999).
3. H.O. Smith, M.F. Tiffany, C.R. Qualls, and C.R. Key The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States: a 24-year population-based study Gynecol. Oncol. 78 2000 97 105
4. C.A. Perez, R.J. Kurman, F.B. Stehman, and J.T. Thigpen Uterine cervix W.J. Hoskins C.A. Perez R.C. Young Principles and practice of gynecologic oncology 1992 Lippincott Philadelphia 591 662
5. J.P. Curtin, J.A. Blessing, K.D. Webster, P.G. Rose, A.R. Mayer, and W.C. Fowler Paclitaxel an active agent in nonsquamous carcinomas of the uterine cervix: a gynecologic oncology group study J. Clin. Oncol. 19 5 2001 1275 1278
6. P.G. Rose, J.A. Blessing, R.E. Buller, R.S. Mannel, and K.D. Webster Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a gynecologic oncology group study Gynecol. Oncol. 89 2003 267 270
7. D.C. DeLong, L.W. Hertel, J. Tang, J.S. Kroin, J.D. Wilson, and J. Terry Antiviral activity of 2′,2′-difluorodeoxycytidine Proc. Ann. Meet. Am. Soc. Microbiol., Washington, DC, March 24-28 1986
8. P. Huang, and W. Plunkett Induction of apoptosis by gemcitabine Semin. Oncol. 22 Suppl. 11 1995 19 25
9. L.W. Hertel, G.B. Boder, J.S. Kroin, S.M. Rinzel, G.A. Poore, and G.C. Toddet Evaluation of the antitumor activity of gemcitabine (2′,2′- difluoro-2′-deoxycytidine) Cancer Res. 50 1990 4417 4422
10. T.S. Lawrence, A. Eisbruch, and D.S. Shewach Gemcitabine-mediated radiosensitization Semin. Oncol. 24 1997 S7-24 S7-28
11. H.A. Burris, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, and M.R. Modiano Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J. Clin. Oncol. 15 1997 2403 2413
12. S. Bretti, E. Manzin, C. Loddo, A. Berruti, S. Bombaci, and G. Vellani Gemcitabine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a phase II study Anticancer Res. 22 2002 3039 3043
13. W.M. Stadler, A. Hayden, H. von der Maase, D. Roychowhury, L. Dogliotti, and L. Seymour Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer Urol. Oncol. 7 2002 153 157
14. G.C. Toner Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel Gynecol. Oncol. 63 1996 89 93
15. P.G. Rose, K. Mossbruger, N. Fusco, M. Smrekar, S. Eaton, and M. Rodriguez Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma Gynecol. Oncol. 88 1 2003 17 21
16. J. Carmichael, K. Possinger, P. Phillip, M. Beykirch, H. Kerr, and J. Walling Advanced breast cancer: a phase II trial with gemcitabine J. Clin. Oncol. 13 11 1995 2731 2736
17. R.J. Schilder, J.A. Blessing, M. Morgan, C.E. Mangan, and J.S. Rader Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group Gynecol. Oncol. 76 2000 204 207
18. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J. Natl. Cancer Inst. 92 2000 205 216
19. S.E. Davidson, R.P. Symonds, D. Lamont, and E.R. Watson Does adenocarcinoma of the uterine cervix have a worse prognosis than squamous carcinoma when treated by radiotherapy? Gynecol. Oncol. 33 1989 23 26
20. P.J. DiSaia, and W.T. Creasman Invasive cervical cancer in clinical gynecologic oncology sixth ed. 2002 Mosby Inc. St. Louis 53 112
21. S. Greggi, G. D'Agostini, D. Smaniotto, D. Genovesi, D. Lorusso, and G. Scambia Letters to the Editor. Gemcitabine is ineffective in recurrent, preirradiated cervical cancer Gynecol. Oncol. 78 2000 76 80
22. W.P. McGuire, J.A. Blessing, D. Moore, S.S. Lentz, and G. Photopulos Paclitaxel has moderate activity in squamous cervix cancer: a gynecologic oncology group study J. Clin. Oncol. 14 1996 792 795
23. A.P. Kudelka, R. Winn, C.L. Edwards, G. Downey, H. Greenberg, and S.R. Dakhil Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix Clin. Cancer Res. 2 1996 1285 1288
24. J.T. Thigpen, J.A. Blessing, W.C. Fowler Jr., and K. Hatch Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix: a gynecologic oncology group study Cancer Treat. Rep. 70 1986 1097 1100
25. G.P. Sutton, J.A. Blessing, P.J. DiSaia, and W.P. McGuire Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a gynecologic oncology group study Gynecol. Oncol. 49 1993 48 50
26. K.Y. Look, J.A. Blessing, F.A. Valea, R. McGehee, A. Manetta, and K.D. Webster Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a gynecologic oncology group study Gynecol. Oncol. 67 1997 255 258
27. J.H. Malfetano, J.A. Blessing, and H.D. Homesley A phase II trial of gallium nitrate (NSC #15200) in nonsquamous cell carcinoma of the cervix: a gynecologic oncology group study Am. J. Clin. Oncol. 18 1995 495 497
28. J. Fiorica, R. Holloway, B. Ndubisi, J. Orr, E. Grendys, and R. Boothby Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix Gynecol. Oncol. 85 2002 89 92
29. K. Noda, H. Sasaki, K. Yamamoto, T. Yamamoto, R. Nishimura, and T. Sugiyama Phase II trial of topotecan for cervical cancer of the uterus Proc. Am. Soc. Clin. Oncol. 15 1996 280 [Abstract #754]